ET-105 PDUFA date: FDA decision expected January 18, 2027

The FDA is expected to decide on ET-105 from Eton Pharmaceuticals, Inc. in adult refractory gastroesophageal reflux disease (rGERD) by the PDUFA target action date of January 18, 2027. For adult refractory gastroesophageal reflux disease (rGERD). NDA filing. Extracted from SEC filing: 8-K

A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.